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2Summary
L-Asparaginase is active in the treatment of acute lymphoblastic leukaemia 
(ALL) through the depletion of serum asparagine. Here we report that median 
AS mRNA levels were higher in acute myeloid leukaemia (AML) than ALL 
blasts in both children and adults, with intermediate levels in normal peripheral
blood mononuclear cells (NPBMC). These results reached significance (one 
way ANOVA, P<0.0001); NPBMC versus child ALL (Tukeys Multiple 
Comparison Test, P<0.05); child ALL versus child AML (P<0.001) and adult 
ALL versus adult AML (P<0.01) and support the hypothesis that selectivity to 
treatment with L-asparaginase is due, at least in part, to lower AS expression. 
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L-asparaginase (L-asp) is an important component in the treatment of 
childhood acute lymphoblastic leukaemia (ALL). Recently the assumption that 
leukaemic cells are sensitive to L-asp due to a relative lack of asparagine 
synthetase (AS) has been questioned (Krejci, et al 2004, Stams, et al 2003). 
Using an RQ RT-PCR assay with transcription binding protein IID/TATA (TBP)
as the internal control we provide evidence to support the original supposition 
that lymphoblasts have significantly lower levels of expression of AS than 
normal peripheral blood mononuclear cells (NPBMC). 
3Materials and methods
Following ethical approval bone marrow samples at diagnosis were obtained 
from 59 children (median 5 years; range 0.6-15.5) and 23 adults (median 29 
years; range 17.7-71) with ALL and 8 children (median 5.2 years; range 1-16) 
and 22 adults (median 57; range 17-84) with acute myeloid leukaemia (AML). 
The presence of more than 80% blasts was confirmed by morphology. 
NPBMC were obtained from 14 healthy volunteers. Mononuclear cells were 
isolated by density gradient centrifugation using Lymphoprep (Nycomed 
Pharma, Oslo, Norway). K562, MOLT-4 and NALM-6 cell lines were grown 
under standard conditions for use as controls. 
Total mRNA was extracted using the RNeasy mini kit (Qiagen, Crawley, UK) 
according to the manufacturer’s protocol. Reverse transcription of 200ng total 
RNA was performed using a Taqman Reverse Transcription kit (Applied 
Biosystems) with random hexomers. Primers and Taqman probe for AS RQ 
RT-PCR, were designed using Primer-Express (Applied Biosystems). Primer 
and probe sequences were as follows; forward –5’-
TCAGCCCGCCACATCAC-3’– (in exon1), reverse –5’-
CAATGAAGCTATAAGCTTTCTTCAAGTG-3’ (spanning exon 2 and 3), probe, 
–5’-CTGACCTGCTTACGCCCAGATTTTCTTCAA-3’ (spanning exon one and 
two). Primers and probe for TBP were purchased as a Taqman pre-developed 
control reagent. 
Standards containing 75, 18.75, 4.69, 1.17, 0.29 and 0.07ng of K562 total 
RNA with reverse transcribed E.coli tRNA as a carrier were assayed for AS
4and TBP in triplicate on 27 separate occasions. CT values (the fractional cycle 
number at which the fluorescence passes the fixed threshold) for each 
standard were obtained using an ABI Prism 5700 sequence detection system 
and the average CT for each point plotted against log standard RNA 
concentration.
Reaction mixtures (82.5µl) contained 41.25µl Taqman PCR universal master 
mix, 900nM AS forward primer, 900nM AS reverse primer, 225nM AS probe 
or 4.13µl of ready synthesised TBP primers and probe and either 7.3µl of 
sample cDNA, 22.5µl of standard cDNA or 3.2µl of calibrator cDNA. Aliquots 
(25 µl) were added to wells of a microplate in triplicate. The thermal cycling 
conditions were 95oC for 10 minutes, 40 cycles at 95oC for 15 seconds and 
60oC for 1 minute.
A calibrator sample was quantified for AS and TBP in each assay. AS gene 
expression relative to the TBP gene were calculated as follows:
Quantity of AS sample / Quantity of AS calibrator
rAS = ---------------------------------------------------------------
Quantity of TBP sample / Quantity of TBP calibrator
Results and Discussion
The reliability of the assay was determined by quantifying AS mRNA levels in 
MOLT-4, NALM 6 and K562 cell lines. Mean rAS values were 0.04, 0.50 and 
50.84 respectively (n=7) Intra-assay coefficients of variation (CV) were 16.5% 
13.4% and 10.1% (n=3). Inter-assay CV values were 32.1%, 9.04% and 
9.97% (n=7). For childhood ALL, rAS values ranged from 0.013 to 0.84 (65-
fold, median=0.17, n=59) and adult ALL 0.07 to 1.55 (22-fold, median=0.19, 
n=23) (figure 1). For childhood AML, rAS values ranged from 0.19 to 9.4 (49-
fold, median=0.47, n=8) and adult AML 0.19 to 2.30 (12-fold, median=0.50, 
n=22). Little variation was observed in NPBMC where values ranged 0.27 to 
0.49 (2-fold, median=0.40, n=14). 
There was a higher median rAS in the AML patient samples than the ALL 
patient samples tested for both children and adults. The median rAS for 
NPBMC was higher than that for children and adults with ALL but less than 
that for children and adults with AML. These results reached significance (one 
way ANOVA following log10 transformation, P<0.0001 and as shown in figure 
1). No significant difference in median rAS was observed comparing adults 
and children with either ALL or AML (p>0.05 in both cases)
No significant difference in rAS was detected between gender, 
immunophenotype, age at presentation or presenting white cell count for 
either adults or children with ALL or AML. No relationship was observed 
between rAS and cytogenetics, including the presence of the t(12;21) 
translocation or percentage blasts in the bone marrow at day 8 of therapy for 
children with ALL (data not shown).
6In 1972 Horowitz and Meister (Horowitz and Meister 1972) suggested that 
leukaemic cells lack AS activity compared with normal cells and therefore rely 
on circulatory asparagine for survival. L-asp depletes asparagine from blood 
and bone marrow, starving the leukaemic cells of asparagine, causing them to 
undergo cell cycle arrest at G1 and ultimately apoptosis (Ueno, et al 1997).  In 
vitro, resistance to L-asp has been shown to be highly correlated with cellular 
AS activity, mRNA and protein content (Hutson, et al 1997) and sensitive cell 
lines made resistant by repeated sub-culturing in sub-lethal doses of L-asp 
display increased AS expression (Kiriyama, et al 1989).
Our results contradict those reported by both Stams (2003) and Krejci (2004) 
in that we found that AS mRNA levels in NPBMC were significantly higher 
than those in lymphoblasts, in line with the expectation from many in vitro
studies. As previously discussed (Krejci, et al 2005a, Krejci, et al 2005b, 
Stams, et al 2005) this may be due to the choice of the endogenous control
used to normalize AS expression. We selected TBP as a suitable control as 
the variation of TBP expression between samples of lymphoid origin has been 
shown to be lower than either GAPDH or 2microglobulin (Lossos, et al 2003)
and in our RQ RT-PCR assay we found that the abundance of TBP was
similar to that of AS. 
In summary, our observations support the original suggestion that AS
expression is lower in lymphoblasts than in NPBMC and that this may explain 
their increased sensitivity to L-asp therapy. 
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8Title and legends to figures
Fig 1. Relative AS mRNA levels (rAS) of samples from children and adults 
with leukaemia and peripheral mononuclear cells from healthy individuals.  
Results are the average of three independent experiments with each sample 
quantified in triplicate. The significance of the comparisons indicated were 
calculated using Tukeys multiple comparison test.
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